Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review

Auer, Rebecca C.; Sivajohanathan, Duvaraga; Biagi, Jim; Conner, James; Kennedy, Erin; May, Taymaa

doi:10.1016/j.ejca.2019.10.034

Cited by 69 publications

(38 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the changed delivery route or warm-up of chemotherapy agents (IP administration or IP hyperthermia therapy) has been also accepted in the certain clinical situations [43,44,[70][71][72][73][74][75]. Moreover, advancing drug development, including poly(adenosine diphosphate (ADP)-ribose) polymerase inhibitors (PARPi) as well as small molecules targeting various kinds of signaling pathway has shown the dramatic improvement in ETOC and PPSC treatment [76][77][78][79][80][81][82][83][84][85][86][87].…”

Section: Current Standard Of Treatmentmentioning

confidence: 99%

“…MITO-7 (Multicentre Italian Trials in Ovarian cancer 7) showed that there was no statistically significant difference of median PFS between dose-dense weekly combination and standard triweekly combination therapy [32]. GOG-0262 showed no statistical difference of the median PFS between dose-dense weekly paclitaxel and triweekly carboplatin with/without adding 15 mg/kg bevacizumab treatment, respectively, and standard triweekly combination therapy [75]. The results from an ICON8 showed that the restricted mean PFS was not statistically significant different among the three groups (dose-dense or standard groups) [33].…”

Section: Previous Studies For Dose-dense Therapymentioning

confidence: 99%

See 1 more Smart Citation

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer

Huang

Chen

Lee

et al. 2020

IJERPH

View full text Add to dashboard Cite

The use of weekly chemotherapy for the treatment of patients with advanced-stage serous-type epithelial Tubo-ovarian cancer (ETOC), and primary peritoneal serous carcinoma (PPSC) is acceptable as the front-line postoperative chemotherapy after primary cytoreductive surgery (PCS). The main component of dose-dense chemotherapy is weekly paclitaxel (80 mg/m2), but it would be interesting to know what is the difference between combination of triweekly cisplatin (20 mg/m2) or triweekly carboplatin (carboplatin area under the curve 5-7 mg/mL per min [AUC 5-7]) in the dose-dense paclitaxel regimen. Therefore, we compared the outcomes of women with Gynecology and Obstetrics (FIGO) stage IIIC ETOC and PPSC treated with PCS and a subsequent combination of dose-dense weekly paclitaxel and triweekly cisplatin (paclitaxel–cisplatin) or triweekly carboplatin using AUC 5 (paclitaxel–carboplatin). Between January 2010 and December 2016, 40 women with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC EOC, FTC, or PPSC were enrolled, including 18 treated with paclitaxel–cisplatin and the remaining 22 treated with paclitaxel–carboplatin. There were no statistically significant differences in disease characteristics of patients between two groups. Outcomes in paclitaxel–cisplatin group seemed to be little better than those in paclitaxel–carboplatin (median progression-free survival [PFS] 30 versus 25 months as well as median overall survival [OS] 58.5 versus 55.0 months); however, neither reached a statistically significant difference. In terms of adverse events (AEs), patients in paclitaxel–carboplatin group had more AEs, with a higher risk of neutropenia and grade 3/4 neutropenia, and the need for a longer period to complete the front-line chemotherapy, and the latter was associated with worse outcome for patients. We found that a period between the first-time chemotherapy to the last dose (6 cycles) of chemotherapy >21 weeks was associated with a worse prognosis in patients compared to that ≤21 weeks, with hazard ratio (HR) of 81.24 for PFS and 9.57 for OS. As predicted, suboptimal debulking surgery (>1 cm) also contributed to a worse outcome than optimal debulking surgery (≤1 cm) with HR of 14.38 for PFS and 11.83 for OS. Based on the aforementioned findings, both regimens were feasible and effective, but maximal efforts should be made to achieve optimal debulking surgery and following the on-schedule administration of dose-dense weekly paclitaxel plus triweekly platinum compounds. Randomized trials validating the findings are warranted.

show abstract

Section: Current Standard Of Treatmentmentioning

confidence: 99%

Section: Previous Studies For Dose-dense Therapymentioning

confidence: 99%

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer

Huang

Chen

Lee

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…Hyperthermic intraperitoneal chemoperfusion (HIPEC) combined with cytoreductive surgery is used for certain types of cancers affecting the peritoneum [ 12 ]. The concept of this method is to provide a short-term circulation of high doses of chemotherapeutic drugs in the peritoneal cavity.…”

Section: Introductionmentioning

confidence: 99%

Modeling of Chemoperfusion vs. Intravenous Administration of Cisplatin in Wistar Rats: Adsorption and Tissue Distribution

et al. 2020

View full text Add to dashboard Cite

Hyperthermic intraperitoneal chemoperfusion (HIPEC) is an established form of locoregional chemotherapy of peritoneum tumors. However, its efficacy and safety status remain a controversy, partially, due to scarce data on pharmacokinetics and toxicity profile of drugs under HIPEC. In the current study, 24 female Wistar rats were randomly assigned to receive cisplatin as HIPEC (n = 12, 20 mg/kg) or intravenously (i.v., n = 9, 4 mg/kg). The subgroups of three animals were used for the initial, intermediate, and late phases of the pharmacokinetic assessment. The animals were sacrificed on days 1 and 5. Blood, liver, kidney, and ovaries were evaluated for platinum content. Histological and immunohistochemical evaluation was undertaken in the liver and kidney. A trend for higher blood plasma platinum levels was observed for HIPEC compared to i.v. Significantly lower (p < 0.001) relative platinum binding to the proteins was observed in HIPEC animals compared to the i.v. administration. A five-fold higher concentration of cisplatin in HIPEC resulted in a ca. 2.5-fold increase in total blood platinum and ca. two-fold increase in blood ultrafitrable platinum (“free” Pt). Immunohistochemistry revealed higher kidney and liver damage after i.v. administration of cisplatin compared to HIPEC, although a five-fold higher dose of cisplatin was applied in HIPEC. Together with relatively lower absorption to the systemic circulation in HIPEC, higher protein binding is probably the primary reason for lower observed toxicity in HIPEC animals.

show abstract

“…Most patients present with advanced disease and synchronous peritoneal metastases (PM), with poor prognosis ( Pavlov et al, 2009 ). The optimal management for patients with newly diagnosed, primary stage III EOC, is a combination of systemic chemotherapy with interval cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) ( Auer et al, 2020 ). Hyperthermic intrathoracic chemotherapy (HITHOC), a palliative targeted surgical therapy for patients with malignant pleural effusion, has also been reported, with acceptable morbidity and overall survival benefit ( Zhou et al, 2017 , Dattatri et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Hyperthermic intraoperative thoracoabdominal chemotherapy for stage IVB epithelial ovarian carcinoma

Brind’Amour

Tremblay

Fortin

et al. 2020

Gynecologic Oncology Reports

View full text Add to dashboard Cite

show abstract

Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review

Cited by 69 publications

References 36 publications

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer

Modeling of Chemoperfusion vs. Intravenous Administration of Cisplatin in Wistar Rats: Adsorption and Tissue Distribution

Hyperthermic intraoperative thoracoabdominal chemotherapy for stage IVB epithelial ovarian carcinoma

Contact Info

Product

Resources

About